Oxford Asset Management LLP Takes Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Oxford Asset Management LLP acquired a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 4th quarter, Holdings Channel.com reports. The firm acquired 23,484 shares of the biopharmaceutical company’s stock, valued at approximately $72,000.

A number of other institutional investors also recently bought and sold shares of the stock. Gateway Wealth Partners LLC bought a new stake in Puma Biotechnology during the fourth quarter valued at about $31,000. Tower Research Capital LLC TRC lifted its position in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 6,351 shares in the last quarter. C2C Wealth Management LLC bought a new position in shares of Puma Biotechnology during the 4th quarter valued at approximately $37,000. Franklin Resources Inc. purchased a new stake in Puma Biotechnology in the 3rd quarter worth approximately $41,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Puma Biotechnology by 42.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,083 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 5,726 shares in the last quarter. 61.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PBYI. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, February 28th. StockNews.com raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Friday.

Puma Biotechnology Stock Down 0.7 %

NASDAQ PBYI opened at $2.98 on Tuesday. Puma Biotechnology, Inc. has a 12 month low of $2.23 and a 12 month high of $5.26. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The stock has a market cap of $147.84 million, a PE ratio of 6.21 and a beta of 1.34. The stock’s 50 day moving average is $3.11 and its 200 day moving average is $3.03.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. The firm had revenue of $59.10 million for the quarter, compared to the consensus estimate of $52.50 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. Research analysts predict that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.